|Bid||208.11 x 800|
|Ask||212.88 x 1000|
|Day's Range||207.10 - 213.49|
|52 Week Range||173.45 - 492.29|
|Beta (5Y Monthly)||1.14|
|PE Ratio (TTM)||47.09|
|Earnings Date||Nov 02, 2022 - Nov 07, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||241.41|
Subscribe to Yahoo Finance Plus to view Fair Value for ILMN
Its sequencing devices are among the most widely distributed in global hospitals and laboratories of all stripes, and its ongoing years-long efforts to develop new technologies place it at the cutting edge of the field, with few notable competitors anywhere in sight. Illumina is currently facing some serious legal trouble in the E.U. to the point where it constitutes a red flag for its near-term performance. To prepare for the possible fine, Illumina is setting aside $453 million.
Zacks.com users have recently been watching Illumina (ILMN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Baron Funds, an asset management firm, published its “Baron Health Care Fund” second quarter 2022 investor letter – a copy of which can be downloaded here. In the quarter ended June 30, 2022, Baron Health Care Fund (the “Fund”) declined 10.00% (Institutional Shares), compared with the 7.43% decline for the Russell 3000 Health Care Index (the […]